Ticker Details
Editas Medicine, Inc. Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes.
IPO Date:	February 3, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$270.22M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.67 | 3.42%
Avg Daily Range (30 D):	$0.11 | 3.82%
Avg Daily Range (90 D):	$0.10 | 4.04%

Institutional Daily Volume
Avg Daily Volume:	1.32M
Avg Daily Volume (30 D):	1.26M
Avg Daily Volume (90 D):	1.5M

Trade Size
Avg Trade Size (Sh.):	114
Avg Trade Size (Sh.) (30 D):	149
Avg Trade Size (Sh.) (90 D):	178

Institutional Trades
Total Institutional Trades:	3,817
Avg Institutional Trade:	$2.01M
Avg Institutional Trade (30 D):	$.66M
Avg Institutional Trade (90 D):	$.85M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.78M
Avg Closing Trade (30 D):	$1.47M
Avg Closing Trade (90 D):	$1.05M
Avg Closing Volume:	160.45K

News

Apr 15, 2026 @ 6:00 PM Neutrolis Appoints Caren Deardorf as Chief Busines... Source: Not Specified

Mar 9, 2026 @ 11:00 AM Editas Medicine Announces Fourth Quarter and Full ... Source: Na

Jan 22, 2026 @ 9:56 AM Genome Editing Market Forecast to Reach $23.6 Bill... Source: Researchandmarkets.Com

Nov 17, 2025 @ 3:00 PM Gene Therapies for Cancer Treatment Market Project... Source: Towards Healthcare

Sep 25, 2025 @ 1:15 PM Healthcare Innovation Accelerates as Four Convergi... Source: Prnewswire

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.17	$-.26	$
Diluted EPS	$-1.17	$-.26	$
Revenue	$38.69M	$2.83M	$24.74M
Gross Profit
Net Income / Loss	$-108.95M	$-24.98M	$-5.62M
Operating Income / Loss	$-108.85M	$-25M	$-7.76M
Cost of Revenue
Net Cash Flow	$6.75M	$M	$-19M
PE Ratio